- Home
- AAM vs TBPH Comparison
AAM vs TBPH Comparison
Compare AAM & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAM
- TBPH
- Stock Information
- Founded
- AAM 2024
- TBPH 2013
- Country
- AAM United States
- TBPH United States
- Employees
- AAM N/A
- TBPH N/A
- Industry
- AAM
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- AAM
- TBPH Health Care
- Exchange
- AAM Nasdaq
- TBPH Nasdaq
- Market Cap
- AAM 457.8M
- TBPH 464.5M
- IPO Year
- AAM 2024
- TBPH N/A
- Fundamental
- Price
- AAM $10.41
- TBPH $10.57
- Analyst Decision
- AAM
- TBPH Buy
- Analyst Count
- AAM 0
- TBPH 4
- Target Price
- AAM N/A
- TBPH $14.50
- AVG Volume (30 Days)
- AAM 32.5K
- TBPH 319.2K
- Earning Date
- AAM 01-01-0001
- TBPH 08-04-2025
- Dividend Yield
- AAM N/A
- TBPH N/A
- EPS Growth
- AAM N/A
- TBPH N/A
- EPS
- AAM 0.30
- TBPH N/A
- Revenue
- AAM N/A
- TBPH $65,266,000.00
- Revenue This Year
- AAM N/A
- TBPH $43.53
- Revenue Next Year
- AAM N/A
- TBPH N/A
- P/E Ratio
- AAM $34.77
- TBPH N/A
- Revenue Growth
- AAM N/A
- TBPH 6.11
- 52 Week Low
- AAM $9.96
- TBPH $7.44
- 52 Week High
- AAM $10.79
- TBPH $11.82
- Technical
- Relative Strength Index (RSI)
- AAM N/A
- TBPH 56.13
- Support Level
- AAM N/A
- TBPH $10.42
- Resistance Level
- AAM N/A
- TBPH $11.00
- Average True Range (ATR)
- AAM 0.00
- TBPH 0.34
- MACD
- AAM 0.00
- TBPH -0.04
- Stochastic Oscillator
- AAM 0.00
- TBPH 10.71
About AAM AA Mission Acquisition Corp. Class A Ordinary Shares
AA Mission Acquisition Corp is a blank check company.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).